Definium Therapeutics (NASDAQ:DFTX) Insider Sells $513,845.07 in Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Mark Sullivan sold 14,051 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $513,845.07. Following the sale, the insider directly owned 494,228 shares in the company, valued at approximately $18,073,917.96. The trade was a 2.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Definium Therapeutics Stock Performance

Shares of NASDAQ DFTX opened at $37.60 on Friday. The stock has a fifty day moving average price of $41.15 and a two-hundred day moving average price of $32.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The firm has a market cap of $5.05 billion, a P/E ratio of -10.96 and a beta of 2.19. Definium Therapeutics, Inc. has a 1 year low of $10.46 and a 1 year high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Research analysts forecast that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wall Street Zen cut shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Canaccord Genuity Group set a $78.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 15th. Needham & Company LLC restated a “buy” rating and set a $66.00 target price on shares of Definium Therapeutics in a report on Monday, September 14th. Finally, Stifel Nicolaus raised their target price on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Definium Therapeutics has a consensus rating of “Buy” and an average target price of $64.88.

Hedge Funds Weigh In On Definium Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new stake in Definium Therapeutics during the 2nd quarter worth about $138,755,000. Avoro Capital Advisors LLC acquired a new position in shares of Definium Therapeutics in the fourth quarter worth about $66,950,000. Bank of New York Mellon Corp boosted its holdings in shares of Definium Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock worth $36,563,000 after buying an additional 24,349 shares during the period. Seven Fleet Capital Management LP purchased a new position in shares of Definium Therapeutics in the second quarter worth approximately $6,992,000. Finally, TD Waterhouse Canada Inc. purchased a new position in shares of Definium Therapeutics in the second quarter worth approximately $1,592,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.